Skip to main content
Fig. 2 | Breast Cancer Research

Fig. 2

From: TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer

Fig. 2

Waterfall plot of response by treatment arm. a Pathologic responses were assessed by comparing the maximum cumulative diameter of the target lesion(s) at the time of diagnosis as assessed by imaging studies with the size of the tumor in the final surgical pathology. b Radiological responses were assessed according to RECIST by breast ultrasound or breast MRI in selected cases (whichever modality was consistently obtained throughout the protocol therapy and most accurately assessed the status of the tumor)

Back to article page